Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Shots:

  • Takeda and Frazier enter into collaboration to launch Phathom Pharmaceuticals to develop & commercialize therapies for gastrointestinal diseases and disorders
  • Phathom to get rights to develop & exclusively commercialize Takeda’s Vonoprazan in the US, EU & Canada plus $90M funds & $50M as debt facility from Frazier & Silicon Valley Bank respectively. Takeda to get upfront as cash & equity, milestones, royalties on sales and will retain its right for Asia
  • Takeda’s vonoprazan is an orally active potassium-competitive acid blocker (P-CAB), blocking the potassium binding site of ATPase indicated for acid-related disorders like GERD, co-promoted by Takeda & Otsuka under 2015 deal

Click here to read full press release/ article | Ref: BusinessWire | Image: Biotechin.Asia